logo
Plus   Neg
Share
Email

Fiat Chrysler : Paolo Carmassi Appointed As CEO Of Comau

Fiat Chrysler Automobiles N.V. (FCAU) announced appointment of Paolo Carmassi as Chief Executive Officer of Comau. Alessandro Nasi will become Comau's Chairman. The new leadership was named at Comau in preparation for its future as a publicly-listed company.

For the past four years, Carmassi has led Malvern Panalytical Ltd., a major provider of scientific instrumentation for materials analysis. Previously, he was head of the Aerospace business in EMEA for Honeywell, where he spent 23 years holding a series of positions of increasing leadership responsibility, in both the automotive and aerospace sectors.

Headquartered in Turin, Italy, Comau provides joining, assembly and machining solutions for both traditional and electric vehicles, and robotized manufacturing including wearable robotics.

The company also offers specialist project management and consultancy services, maintenance and training, and operates through an international network of 7 centers, 5 digital hubs, 8 production plants, employing over 9,000 people in 14 countries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT